1. Lung-heart toxicity in a randomized clinical trial of hypofractionated image guided radiation therapy for breast cancer
- Author
-
Hilde Van Parijs, Elsa Cecilia-Joseph, Olena Gorobets, Guy Storme, Nele Adriaenssens, Benedicte Heyndrickx, Claire Verschraegen, Nam P. Nguyen, Mark De Ridder, and Vincent Vinh-Hung
- Subjects
time-to-alteration analysis ,breast neoplasms ,targeted radiotherapy ,pulmonary injury ,heart damage ,health-related quality of life ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundTomoBreast hypothesized that hypofractionated 15 fractions/3 weeks image-guided radiation therapy (H-IGRT) can reduce lung-heart toxicity, as compared with normofractionated 25-33 fractions/5-7 weeks conventional radiation therapy (CRT).MethodsIn a single center 123 women with stage I-II operated breast cancer were randomized to receive CRT (N=64) or H-IGRT (N=59). The primary endpoint used a composite four-items measure of the time to 10% alteration in any of patient-reported outcomes, physician clinical evaluation, echocardiography or lung function tests, analyzed by intention-to-treat.ResultsAt 12 years median follow-up, overall and disease-free survivals between randomized arms were comparable, while survival time free from alteration significantly improved with H-IGRT which showed a gain of restricted mean survival time of 1.46 years over CRT, P=0.041.DiscussionThe finding establishes TomoBreast as a proof-of-concept that hypofractionated image-guided radiation-therapy can improve the sparing of lung-heart function in breast cancer adjuvant therapy without loss in disease-free survival. Hypofractionation is advantageous, conditional on using an advanced radiation technique. Multicenter validation may be warranted.Trial registrationhttps://clinicaltrials.gov/ct2/show/NCT00459628. Registered 12 April 2007.
- Published
- 2023
- Full Text
- View/download PDF